| Description | AKOS037652256 can be used as a TRPML modulator for the treatment of diseases associated with TRPML activity such as lysosomal accumulation disorders, muscular dystrophy, common age-related neurodegenerative diseases, oxidative stress or reactive oxygen species (ROS)-related diseases and ageing. |
| In vitro | AKOS037652256（0.1-3 μM）足以诱导TFEB向核内转移（核/细胞质比例随剂量增加而上升）。[2] |
| Target activity | TRPML:< = 2 µM(AC50), TRPML1:< = 2 µM(AC50) |
| molecular weight | 553.07 |
| Molecular formula | C24H26ClFN4O4S2 |
| CAS | 2171065-77-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 5.53 mg/mL (10 mM), Sonication is recommended. |
| References | 1. Fortanet, et al. Heterocyclic compounds as TRPML modulators and their preparation. WO2021127337. 2. Liang, et al. Preparation of piperazine derivatives as TRPML modulators for the treatment of diseases. WO2018005713A1. |